Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease

<p dir="ltr">Accumulation of α-synuclein into toxic oligomers or fibrils is implicated in dopaminergic neurodegeneration in Parkinson’s disease. Here we performed a high-throughput, proteome-wide peptide screen to identify protein-protein interaction inhibitors that reduce α-synuclei...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Satra Nim (11540447) (author)
مؤلفون آخرون:	Darren M. O’Hara (9201761) (author), Carles Corbi-Verge (527968) (author), Albert Perez-Riba (5004785) (author), Kazuko Fujisawa (11692038) (author), Minesh Kapadia (582056) (author), Hien Chau (355945) (author), Federica Albanese (19482364) (author), Grishma Pawar (10666899) (author), Mitchell L. De Snoo (19482367) (author), Sophie G. Ngana (19482370) (author), Jisun Kim (837555) (author), Omar M. A. El-Agnaf (8809331) (author), Enrico Rennella (2083291) (author), Lewis E. Kay (135973) (author), Suneil K. Kalia (9201773) (author), Lorraine V. Kalia (9201770) (author), Philip M. Kim (11540462) (author)
منشور في:	2023
الموضوعات:	Biomedical and clinical sciences Clinical sciences Neurosciences Pharmacology and pharmaceutical sciences α-Synuclein Parkinson’s Disease Toxic Oligomers Protein-Protein Interaction Inhibitors CHarged Multivesicular body Protein 2B (CHMP2B) Preclinical Models C. elegans Rat Models
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

كن أول من يترك تعليقا!

Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease

مواد مشابهة